AbbVie · 13 hours ago
2026 Investigative Toxicology Complex In Vitro Models Intern (PhD)
AbbVie is a pharmaceutical company dedicated to discovering and delivering innovative medicines to tackle serious health issues. The Investigative Toxicology Complex In Vitro Models Intern will work with the Molecular Toxicology group to develop and apply in vitro models for safety investigations, gaining hands-on experience in cellular and molecular biology techniques.
BiotechnologyFinancial ServicesHealth CareMedicalPharmaceuticalVenture Capital
Responsibilities
Execute and analyze experiments to evaluate drug-induced changes in expression
Use complex in vitro models to investigate toxicities associated with compounds
Work collaboratively with team members to design experiments and explore data
Communicate updates through written reports and oral presentations
Qualification
Required
Currently enrolled in university, pursuing a PhD in toxicology, cellular and molecular biology, or other related field
Must be enrolled in university for at least one semester following the internship
Must have familiarity with cellular and molecular biology
Preferred
Expected graduation date between December 2026 – June 2027
Experience with cell culture or complex in vitro models
Benefits
Competitive pay
Relocation support for eligible students
Select wellness benefits and paid holiday / sick time
Potential for publication co-authorship
Opportunity to connect with AbbVie leaders and scientists
Company
AbbVie
AbbVie is a biopharmaceutical company focused on immunology, oncology, neuroscience, virology, and aesthetics. It is a sub-organization of AbbVie.
H1B Sponsorship
AbbVie has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (273)
2024 (190)
2023 (225)
2022 (284)
2021 (186)
2020 (186)
Funding
Current Stage
Public CompanyTotal Funding
$15B2024-02-27Post Ipo Debt· $15B
2023-03-08Post Ipo Equity· $0.25M
2012-12-20IPO
Leadership Team
Recent News
2026-01-17
MedCity News
2026-01-17
Company data provided by crunchbase